Etoposide treatment in secondary hemophagocytic syndrome: impact on healthcare-associated infections and survival.

ABSTRACT:

Background

Etoposide remains the cornerstone of symptomatic management of critically ill patients with secondary hemophagocytic syndrome (sHS). Risk of healthcare-associated infections (HAIs) in this setting with etoposide has never been assessed. We sought to evaluate the association between etoposide administration, HAIs occurrence and survival in critically ill adult patients with sHS. In this retrospective single-center study conducted in a university hospital ICU between January 2007 and March 2020, all consecutive patients with sHS were included. HAIs were defined as any microbiologically documented infection throughout ICU stay. Competing risk survival analysis was performed to determine factors associated with HAIs. Propensity score-based overlap weighting was performed to

SUBMITTER: Dupont T 

PROVIDER: S-EPMC9616615 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature